BPC-157: the body protection compound, explained

What BPC-157 is

BPC-157 stands for Body Protection Compound-157, a synthetic pentadecapeptide — a chain of 15 amino acids. It is often described as a "stable gastric pentadecapeptide," said to be a partial sequence related to a protein found in human gastric juice (the exact parent protein is not consistently named in the peer-reviewed literature). It is sold in two salt forms, BPC-157 acetate and BPC-157 arginate; vendor claims that one is meaningfully more stable than the other are not independently established.

It is not an approved drug — there is no brand name, no prescription form, and no pharmacy-grade product. It is sold gray-market as a "research chemical," which is the context for everything below.

What the evidence actually shows

This is the part most pages overstate, so here is the honest version. The efficacy evidence for BPC-157 is overwhelmingly preclinical — rodent and in-vitro, with some dog data. In animal models it has shown accelerated healing of tendon, ligament, muscle and gut tissue, and pro-angiogenic effects via the VEGFR2–Akt–eNOS pathway and the nitric-oxide system. Those mechanisms are real in animals and cells.

What does not exist is robust human evidence. There are no large or randomized controlled human trials. The published human data amounts to a handful of tiny, uncontrolled pilot reports (a 2021 knee-pain pilot, a 2024 interstitial-cystitis series, a 2025 two-person infusion safety note). Anti-doping bodies (USADA) note that proper clinical-trial data is conspicuously absent. The honest reading: BPC-157 is investigational and unproven in humans — the animal signal is interesting, but it has not been demonstrated to work, or to be safe, at human scale.

The math

Because BPC-157 ships (in the research market) as a lyophilized powder, any use involves reconstitution arithmetic — the same arithmetic the peptide reconstitution calculator does for any vial. BPC-157 is dosed in micrograms, so the conversion matters. Worked example, presented purely as arithmetic:

Concentration is just milligrams divided by millilitres, and units are just hundredths of a millilitre on a U-100 insulin syringe. Change the water volume and every number moves: the same 5 mg vial with 5 mL gives 1 mg/mL (so 250 mcg = 25 units, a larger, easier-to-measure draw). The reconstitution calculator converts vial size + water + target into exact syringe units (and works in reverse). The micrograms above are illustrative arithmetic, not a recommended dose — community protocols commonly report around 250–500 mcg/day, but no validated human dose exists.

Half-life & the duration puzzle

In the only published pharmacokinetic study (rats and dogs — there is no human PK data), BPC-157's elimination half-life was short: roughly 15 minutes intravenously in rats and about 5 minutes in dogs, under 30 minutes by injection, with intramuscular bioavailability around 14–19% in rats and 45–51% in dogs. It clears mainly through urine and bile.

The puzzle is that effects in animal studies persist far longer than a minutes-long plasma half-life would predict — the mechanism for that durability is not established. Because of this, a half-life curve is less informative here than for a long-acting weekly peptide; but you can still visualize any half-life and dosing interval in the half-life visualizer if you want to see how a short half-life behaves with daily dosing.

Storage & handling

• Lyophilized (powder, unreconstituted): kept frozen for long-term storage; freeze-dried peptide is the most stable form and is typically stored cold and away from light.
• Reconstituted (in bacteriostatic water): refrigerated at 2–8°C (36–46°F), not frozen — freeze/thaw cycles can damage peptide bonds. Reconstituted peptides in bacteriostatic water are commonly assigned a beyond-use window of about four weeks.
• Reconstitution technique: swab the stopper, add water slowly down the vial wall (not onto the powder), and swirl gently rather than shake until dissolved.
• Quality honesty: with unregulated "research chemical" material, neither label accuracy, purity, nor sterility can be assumed — the FDA has cautioned specifically about contamination in gray-market peptide products.

Stacking — the "Wolverine stack"

BPC-157 is most commonly combined with TB-500 (a thymosin-β4 fragment) in what the community calls the "Wolverine stack" for soft-tissue and recovery goals. This is community practice, not clinical guidance — there are no human trials of the combination, and TB-500 is likewise unapproved and WADA-banned. In OptiPin a stack like this is tracked as two separate compounds, each with its own schedule, dose log and vial inventory.

Tracking BPC-157 in OptiPin

If you are tracking a healing-peptide protocol, OptiPin treats it like any other entry — without endorsing it:

• Dose log + reminders — record each injection on a daily or per-protocol cadence and get reminded on the due day, with site rotation.
• Symptom & recovery tracking — log the specific outcome you care about (e.g. a tendon-pain score) over time so a trend lines up against actual dosing — the only honest way to judge an unproven compound on yourself.
• OptiInsight analysis — OptiPin's AI reads the full record (doses, symptoms, labs) and surfaces what moved with what.
• Vial & supply tracking — log the reconstituted vial; OptiPin estimates remaining volume, doses left, and an empty date.
• Built-in reconstitution math — the same calculator covered above is in the app, so the microgram-to-syringe-unit conversion is one tap.